Core Insights - The appointment of Dr. Veet Misra as Chief Financial Officer and Mr. Huang Zhi as Senior Vice President of Global Corporate Development & Finance marks a significant step for Ascentage Pharma in its global expansion efforts [1][2] - The company aims to enhance its influence in the global capital markets and improve corporate governance through the expertise of the new executives [1][3] Group 1: Executive Appointments - Dr. Veet Misra has over 20 years of investment banking experience, previously serving as Managing Director at Cantor Fitzgerald, focusing on the biopharmaceutical sector [2] - Mr. Huang Zhi brings over 20 years of multinational corporate management experience, having served as CFO for BeiGene in the Greater China and Asia-Pacific regions [3] Group 2: Strategic Goals - The company is positioned as a leader in the field of apoptosis-targeted therapies and aims to leverage its dual listing in Hong Kong and the U.S. to enhance its global presence [1][2] - The new executives are expected to accelerate the global development of the company's innovative pipeline and improve resource integration for better commercial outcomes [2][3]
亚盛医药（06855）任命Veet Misra博士为首席财务官 任命黄智为全球企业发展&财务高级副总裁